Newer inotropic agents for decompensated heart failure

ACC Current Journal Review

Volumn 8, Issue 4, 1999, Pages 35-38

  Kieso, Hassan A ^a   Silver, Marc A ^a  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENYLATE CYCLASE; AMRINONE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CALCIUM CHANNEL; CALCIUM SENSITIZER; CYCLIC AMP; DIGOXIN; DOBUTAMINE; DOPAMINE; ENKEPHALINASE INHIBITOR; ENOXIMONE; GROWTH HORMONE; IBOPAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; PROTEIN; PROTEIN KINASE; THYROID HORMONE DERIVATIVE; TOBORINONE; TROPONIN C; UNINDEXED DRUG; XAMOTEROL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART CONTRACTION; HEART FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0032869321     PISSN: 10621458     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1062-1458(99)00018-5     Document Type: Article

References (14)

1. Wagoner LE, Walsh RA. Inotropic therapy for systolic heart failure. Compr Ther 1995;21:367-77.
2. Nielsen-Kudsk JE, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol 1995;26 (Suppl 1):S77-84.
3. O'Connor CM, Gattis WA, Swedberg K. Current and novel pharmacological approaches in advanced heart failure. Am Heart J 1998;135:S249-63.
4. Semeniuk LM, Belenkie I, Tyberg JV. Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. Circulation 1998;98:58-63.
5. Bito H, Kato N, Maruyama K, Kadotani H, Ogawa R. Effects of toborinone on systemic circulation in patients under general anesthesia. Masui 1997;46:900-9.
6. Stevenson LW. Inotropic therapy for heart failure. N Engl J Med 1998;339:1848-50.
7. Cohn J, Goldstein SO, Greenberg BH, et al. A dose dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-6.
8. Lee JA, Allen DG. Calcium sensitisers: Mechanisms of action and potential usefulness as inotropes. Cardiovasc Res 1997;36:10-20.
9. Kubo SH. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Cardiology 1997;88 (Suppl 2):21-7.
10. Hasenfuss G, Pieske B, Castell M, Kretschmann B. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7.
11. Stein BC, Levin RL. Natriuretic peptides: physiology, therapeutic potential and risk stratification in ischemic heart disease. Am Heart J 1998;35:914-22.
12. Abraham WT, Johnson AD, Wagoner L, Givertz MM, Horton DP. Neseritide (Human B-type natriuretic peptide) improves symptoms and hemodynamics in NYHA Class III and IV heart failure. J Am Coll Cardiol 1999;33 (Suppl A):188A.
13. Morkin E, Pennock G, Raya T, Bahl J, Goldman S. Development of a thyroid hormone analogue for the treatment of congestive heart failure. Thyroid 1996;6:521-6.
14. Ross J. Growth hormone, cardiomyocyte contractile reserve, and heart failure. Circulation 1999;99:15-17.